<bill session="115" type="h" number="2641" updated="2017-07-29T07:17:23Z">
  <state datetime="2017-05-24">REFERRED</state>
  <status>
    <introduced datetime="2017-05-24"/>
  </status>
  <introduced datetime="2017-05-24"/>
  <titles>
    <title type="short" as="introduced">Promoting Life-Saving New Therapies for Neonates Act of 2017</title>
    <title type="short" as="introduced">Promoting Life-Saving New Therapies for Neonates Act of 2017</title>
    <title type="official" as="introduced">To promote the development of safe drugs for neonates.</title>
    <title type="display">Promoting Life-Saving New Therapies for Neonates Act of 2017</title>
  </titles>
  <sponsor id="412445"/>
  <cosponsors>
    <cosponsor id="412615" joined="2017-06-21"/>
    <cosponsor id="412250" joined="2017-07-28"/>
    <cosponsor id="412689" joined="2017-06-13"/>
    <cosponsor id="412517" joined="2017-06-13"/>
    <cosponsor id="412272" joined="2017-06-13"/>
    <cosponsor id="412613" joined="2017-06-13"/>
    <cosponsor id="412382" joined="2017-06-07"/>
    <cosponsor id="412278" joined="2017-06-21"/>
    <cosponsor id="412284" joined="2017-06-21"/>
    <cosponsor id="412583" joined="2017-06-13"/>
    <cosponsor id="400218" joined="2017-07-28"/>
    <cosponsor id="412290" joined="2017-06-21"/>
    <cosponsor id="412293" joined="2017-05-24"/>
    <cosponsor id="412662" joined="2017-07-25"/>
    <cosponsor id="412632" joined="2017-06-13"/>
    <cosponsor id="400290" joined="2017-06-07"/>
    <cosponsor id="400309" joined="2017-06-07"/>
    <cosponsor id="412303" joined="2017-07-25"/>
    <cosponsor id="412523" joined="2017-06-13"/>
    <cosponsor id="412633" joined="2017-06-21"/>
    <cosponsor id="412647" joined="2017-06-13"/>
    <cosponsor id="412405" joined="2017-07-13"/>
  </cosponsors>
  <actions>
    <action datetime="2017-05-24">
      <text>Introduced in House</text>
    </action>
    <action datetime="2017-05-24" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2017-05-26">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Child health"/>
    <term name="Congressional oversight"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government studies and investigations"/>
    <term name="Health promotion and preventive care"/>
    <term name="Medical research"/>
  </subjects>
  <amendments/>
  <summary date="2017-05-24T04:00:00Z" status="Introduced in House">Promoting Life-Saving New Therapies for Neonates Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to award the sponsor of a new drug or biological product for the treatment of newborns a neonatal drug exclusivity voucher upon approval of the medication. A neonatal drug exclusivity voucher is a transferable voucher for a one-year extension of all existing patents and marketing exclusivities for a brand name medication. For a sponsor to be eligible for a voucher, the new medication must: (1) treat a condition identified in the Priority List of Critical Needs for Neonates required under this bill, and (2) have been studied in newborns.

A voucher may be revoked if the new medication is not marketed in the United States within one year of approval.

A voucher may not be used: (1) to extend the marketing exclusivity period for a drug for which the FDA requires an assessment of the safety and effectiveness in newborns, or (2) on the same product as a priority review voucher.

A sponsor intending to use a voucher must notify the FDA at least 15 months before the expiration of the patents or exclusivity to be extended.

The Government Accountability Office must study the effectiveness of this voucher program.</summary>
  <committee-reports/>
</bill>
